Hepatology International-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249308, encodeId=89d81249308cd, content=偏重的研究方向：肝脏 经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a762575436, createdName=12591279m60暂无昵称, createdTime=Fri Sep 16 11:05:25 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229964, encodeId=0b8b122996481, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21975472039, createdName=是技师不是医师, createdTime=Fri Jul 01 15:30:42 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

2023-12-28 ms4000001768031770 来自广东省

2023降区了，成3区的了

18 0

[GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249308, encodeId=89d81249308cd, content=偏重的研究方向：肝脏 经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a762575436, createdName=12591279m60暂无昵称, createdTime=Fri Sep 16 11:05:25 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229964, encodeId=0b8b122996481, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21975472039, createdName=是技师不是医师, createdTime=Fri Jul 01 15:30:42 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

2022-08-14 ms6000001864840275

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肝脏
经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！

62 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249308, encodeId=89d81249308cd, content=偏重的研究方向：肝脏 经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a762575436, createdName=12591279m60暂无昵称, createdTime=Fri Sep 16 11:05:25 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229964, encodeId=0b8b122996481, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21975472039, createdName=是技师不是医师, createdTime=Fri Jul 01 15:30:42 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

2021-03-01 1dd96cb3m86(暂无匿称)

审稿速度:1.0 | 投稿命中率:25.0
经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。

136 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249308, encodeId=89d81249308cd, content=偏重的研究方向：肝脏 经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a762575436, createdName=12591279m60暂无昵称, createdTime=Fri Sep 16 11:05:25 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229964, encodeId=0b8b122996481, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21975472039, createdName=是技师不是医师, createdTime=Fri Jul 01 15:30:42 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

2022-04-10 苏苏sci

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肝癌;临床
经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的

68 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249308, encodeId=89d81249308cd, content=偏重的研究方向：肝脏 经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a762575436, createdName=12591279m60暂无昵称, createdTime=Fri Sep 16 11:05:25 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229964, encodeId=0b8b122996481, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21975472039, createdName=是技师不是医师, createdTime=Fri Jul 01 15:30:42 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

2022-08-20 YJJJJJ

偏重的研究方向：手术;肝癌;临床
经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。

43 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249308, encodeId=89d81249308cd, content=偏重的研究方向：肝脏 经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a762575436, createdName=12591279m60暂无昵称, createdTime=Fri Sep 16 11:05:25 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229964, encodeId=0b8b122996481, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21975472039, createdName=是技师不是医师, createdTime=Fri Jul 01 15:30:42 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

2023-06-25 嘻嘻号来自江苏省

2周了，状态还是正在提交给杂志，太慢了

39 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249308, encodeId=89d81249308cd, content=偏重的研究方向：肝脏 经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a762575436, createdName=12591279m60暂无昵称, createdTime=Fri Sep 16 11:05:25 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229964, encodeId=0b8b122996481, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21975472039, createdName=是技师不是医师, createdTime=Fri Jul 01 15:30:42 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

2022-04-20 1821f639cdm

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：肝脏;肿瘤;临床
经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒

70 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249308, encodeId=89d81249308cd, content=偏重的研究方向：肝脏 经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a762575436, createdName=12591279m60暂无昵称, createdTime=Fri Sep 16 11:05:25 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229964, encodeId=0b8b122996481, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21975472039, createdName=是技师不是医师, createdTime=Fri Jul 01 15:30:42 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

2021-10-18 ms7625496543595098

分数这么高的杂志为啥是中科院4区的呢

73 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249308, encodeId=89d81249308cd, content=偏重的研究方向：肝脏 经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a762575436, createdName=12591279m60暂无昵称, createdTime=Fri Sep 16 11:05:25 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229964, encodeId=0b8b122996481, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21975472039, createdName=是技师不是医师, createdTime=Fri Jul 01 15:30:42 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

2022-09-16 12591279m60暂无昵称

偏重的研究方向：肝脏
经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept

107 0

[GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝脏 经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌;临床 经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床 经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1212906, encodeId=5d6a121290653, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肝脏;肿瘤;临床 经验分享：年文章数：73，投稿相对难，每年发表数量太少，排的稿号数量又很大，很佛系的期刊，pubmed上看了近几年的文章，综述偏多，投的生信分析，等待时间约4周，编辑很委婉的建议投其他期刊，婉拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/24/c4699d591a16710e3be839693351aaf5.jpg, createdBy=41ed2099615, createdName=1821f639cdm, createdTime=Wed Apr 20 17:51:05 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061441, encodeId=e8b81061441d8, content=分数这么高的杂志为啥是中科院4区的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/39439D60C1618DE672C0C92941D70C8F/100, createdBy=8eda2086410, createdName=ms7625496543595098, createdTime=Mon Oct 18 11:40:34 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249308, encodeId=89d81249308cd, content=偏重的研究方向：肝脏 经验分享：22 Jul 2022 Submitted to Journal 25 Jul 2022 With Editor 28 Jul 2022 With Editor 31 Jul 2022 Under Review 16 Aug 2022 Major Revision 29 Aug 2022 Revision Submitted to Journal 30 Aug 2022 With Editor 01 Sep 2022 Under Review 09 Sep 2022 Under Review 12 Sep 2022 Decision in Process 15 Sep 2022 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a762575436, createdName=12591279m60暂无昵称, createdTime=Fri Sep 16 11:05:25 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229964, encodeId=0b8b122996481, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21975472039, createdName=是技师不是医师, createdTime=Fri Jul 01 15:30:42 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

2022-07-01 是技师不是医师

无

47 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务